Barinthus Biotherapeutics PLC

What they do

Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for autoimmune and inflammatory diseases. Its lead candidate, VTP-1000, is in Phase 1 trials for celiac disease, using its proprietary SNAP-TI platform designed to restore immune tolerance. The company also has VTP-300, a Phase 2 candidate for chronic hepatitis B, which it is seeking partnerships for.

Revenue drivers

• VTP-1000 (celiac disease) — Lead pipeline asset; no revenue yet, Phase 1 trial AVALON completed enrollment.
• VTP-300 (chronic hepatitis B) — Phase 2 candidate; company exploring partnership opportunities, no revenue recognized.
• SNAP-TI platform — Proprietary platform for immune tolerance; potential for multiple I&I indications beyond celiac disease.

Recent performance

For Q2 2026, the company reported no revenue and a net loss of $66.4 million for full-year 2025. Cash, cash equivalents, and restricted cash were $59.6 million as of June 30, 2026, down from $67.2 million at March 31, 2026. R&D expenses were $3.9 million in Q2 2026, up from $3.6 million in Q1 2026. The company completed enrollment in the MAD portion of the Phase 1 AVALON trial and expects topline data in Q4 2026.

Strategy

The company is prioritizing the development of VTP-1000 for celiac disease and exploring partnerships for VTP-300. It is also progressing a proposed merger with Clywedog Therapeutics, which is expected to close in the second half of 2026. Upon closing, the combined company will be renamed Clywedog Therapeutics Holdings, Inc. and is expected to trade under the ticker 'CLYD' on Nasdaq. The combined company's estimated cash runway is expected to extend through 2027, supported by existing cash and additional investments from OrbiMed and Torrey Pines Investments.

Risks

• Nasdaq delisting risk — Received extension until December 28, 2026 to regain compliance with bid price requirement; ADSs transferred to Nasdaq Capital Market.
• Merger completion risk — Completion of the Clywedog merger is subject to multiple conditions, including shareholder approvals, regulatory clearances, and listing approval; failure would have material adverse effect.
• Clinical trial risk — VTP-1000 is in Phase 1; topline data expected Q4 2026, but results may not support further development.
• Cash burn risk — Operating cash flow negative $48.0 million in 2025; cash resources may not be sufficient if expenses rise or trials delay.

Outlook

Management expects to report topline data from the MAD portion of the Phase 1 AVALON trial in Q4 2026 and anticipates closing the Clywedog merger in the second half of 2026. The company also expects its available resources to fund operations for at least the next 12 months from the date of issuance of the financial statements. An abstract on Phase 1 SAD data for VTP-1000 will be presented at ACG in October 2026.